July 3, 2024
A lot has happened since the onset and passing of the COVID-19 vaccine national public health emergency. Decentralized trials were a hot item, and Curavit was one of a few startup ventures helping sponsors to decentralize their research, bringing studies to the community and even the home. But a lot has changed since the passing of the pandemic as hybrid studies remain the norm—that is, studies that include traditional elements plus digital tools for decentralized engagement. Enter Curavit, a serious decentralized contract research organization (CRO) led by pedigreed operators.
Both CEO Joel Morse and President and Chief Commercial Officer Dave Hanaman were behind the clinical trials technology support and services company C3i Healthcare Connections, a Division of Telerx. The pair and colleagues scaled up a global high-quality services organization and understand the challenges of execution in Food and Drug Administration regulated environments.
